{"classes":[{"categories":[{"measurements":[{"comment":"Median not reached as insufficient progression events among responders","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"EBV positive related gastric cancer"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"24.90","upperLimit":"NA","value":"44.25"},{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG001","lowerLimit":"10.45","upperLimit":"NA","value":"34.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"HPV positive SCCHN"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"3.68","upperLimit":"27.93","value":"18.23"},{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG002","lowerLimit":"3.58","upperLimit":"NA","value":"3.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Other anogenital HPV associated cancers"},{"categories":[{"measurements":[{"comment":"Median not reached as insufficient progression events among responders","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"SCCHN I-O naive"},{"categories":[{"measurements":[{"comment":"Median not reached as insufficient progression events among responders and Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"35.29","upperLimit":"NA","value":"NA"},{"comment":"Median not reached as insufficient progression events among responders and Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG001","lowerLimit":"8.67","upperLimit":"NA","value":"NA"},{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG002","lowerLimit":"15.28","upperLimit":"NA","value":"34.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Randomized"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG002","lowerLimit":"15.28","upperLimit":"NA","value":"34.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Pooled"},{"categories":[{"measurements":[{"comment":"Lower limit and Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"4.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Vaginal/Vulvar"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"16.72","upperLimit":"NA","value":"60.62"},{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG001","lowerLimit":"10.38","upperLimit":"NA","value":"25.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"MCC"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG000","lowerLimit":"3.68","upperLimit":"NA","value":"9.46"},{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG001","lowerLimit":"5.55","upperLimit":"NA","value":"19.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"NPC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Duration of response (DoR) is defined as the time from first confirmed response (complete response or partial response) to the date of the initial objectively documented tumor progression as determined per investigator assessment using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants with the following diseases will be assessed:\n\n1. EBV positive related gastric cancer;\n2. HPV positive SCCHN;\n3. Other anogenital HPV associated cancers;\n4. GYN (Cervical, Vaginal, Vulvar) carcinoma;\n5. Merkel cell carcinoma (MCC);\n6. Nasopharyngeal carcinoma (NPC) NOTE: \"Cervical, Randomized\" and \"Cervical, Pooled\" are not mutually exclusive categories.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab IV over 30 minutes at 240 mg every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG000","title":"Metastatic Monotherapy"},{"description":"Nivolumab 3 mg/kg IV over 30 minutes every 2 weeks + Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG001","title":"Metastatic Combo A"},{"description":"Nivolumab 1 mg/kg IV over 30 minutes + Ipilimumab 3 mg/kg IV over 30 minutes every 3 weeks for 4 doses followed by Nivolumab 240 mg IV over 30 minutes every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG002","title":"Metastatic Combo B"},{"description":"Nivolumab 240 mg IV over 30 minutes + BMS-986016 (Relatlimab) 80 mg IV over 60 minutes administered every 2 weeks for a maximum of 24 months, or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG003","title":"Metastatic Combo C"},{"description":"Daratumumab 16 mg/kg IV weekly for the first 8 weeks. Starting at Week 3, Nivolumab 240 mg IV over 30 minutes every 2 weeks. Daratumumab 16 mg/kg every 2 weeks from Weeks 9-24. Starting at Week 25, Nivolumab 480 mg IV flat dose over 30 minutes every 4 weeks; daratumumab 16 mg/kg every 4 weeks for a maximum of 24 months or until progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG004","title":"Metastatic Combo D"}],"paramType":"MEDIAN","populationDescription":"All complete and partial responders in the metastatic cohorts","reportingStatus":"POSTED","timeFrame":"From first confirmed response (complete response or partial response) to the date of the initial objectively documented tumor progression or death due to any cause, whichever occurs first (Up to 83 months)","title":"Metastatic: Investigator-Assessed Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}